Legis Daily

A bill to amend the Federal Food, Drug, and Cosmetic Act and Securities Exchange Act of 1934 to prevent the inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and with respect to drug innovation, and for other purposes.

USA115th CongressS-3738| Senate 
| Updated: 12/11/2018
Orrin G. Hatch

Orrin G. Hatch

Republican Senator

Utah

Cosponsors (1)
Thomas Tillis (Republican)

Health, Education, Labor, and Pensions Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Hatch-Waxman Integrity Act of 2018 This bill amends the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent a generic drug or biosimilar manufacturer from using a specific review process for challenging pharmaceutical drug or biologic patents.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Dec 11, 2018

Latest Companion Bill Action

HR 115-7251
Introduced in House
Dec 11, 2018
Introduced in Senate
Dec 11, 2018
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • December 11, 2018

    Latest Companion Bill Action

    HR 115-7251
    Introduced in House


  • December 11, 2018
    Introduced in Senate


  • December 11, 2018
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Health

Related Bills

  • HR 115-7251: To amend the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent the inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and with respect to drug innovation, and for other purposes.
Administrative remediesDrug safety, medical device, and laboratory regulationFraud offenses and financial crimesIntellectual propertyLicensing and registrationsPrescription drugsSecurities

A bill to amend the Federal Food, Drug, and Cosmetic Act and Securities Exchange Act of 1934 to prevent the inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and with respect to drug innovation, and for other purposes.

USA115th CongressS-3738| Senate 
| Updated: 12/11/2018
Hatch-Waxman Integrity Act of 2018 This bill amends the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent a generic drug or biosimilar manufacturer from using a specific review process for challenging pharmaceutical drug or biologic patents.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Dec 11, 2018

Latest Companion Bill Action

HR 115-7251
Introduced in House
Dec 11, 2018
Introduced in Senate
Dec 11, 2018
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • December 11, 2018

    Latest Companion Bill Action

    HR 115-7251
    Introduced in House


  • December 11, 2018
    Introduced in Senate


  • December 11, 2018
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Orrin G. Hatch

Orrin G. Hatch

Republican Senator

Utah

Cosponsors (1)
Thomas Tillis (Republican)

Health, Education, Labor, and Pensions Committee

Health

Related Bills

  • HR 115-7251: To amend the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent the inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and with respect to drug innovation, and for other purposes.
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Administrative remediesDrug safety, medical device, and laboratory regulationFraud offenses and financial crimesIntellectual propertyLicensing and registrationsPrescription drugsSecurities